Document is current
Any future updates will be listed below
-
Authors
Lun, Xiao-Kang
Sheng, Kuanwei https://orcid.org/0000-0002-7155-9915
Yu, Xueyang
Lam, Ching Yeung https://orcid.org/0009-0006-4506-5432
Gowri, Gokul https://orcid.org/0000-0003-0911-6889
Serrata, Matthew
Zhai, Yunhao
Su, Hanquan
Luan, Jingyi
Kim, Youngeun
Ingber, Donald E. https://orcid.org/0000-0002-4319-6520
Jackson, Hartland W. https://orcid.org/0000-0001-6423-2415
Yaffe, Michael B. https://orcid.org/0000-0002-9547-3251
Yin, Peng https://orcid.org/0000-0002-2769-6357
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (UH3CA255133, DP1GM133052, R01GM124401, RF1MH124606, RF1MH128861, ES028374, CA226898)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P400PB_199243)
Ovarian Cancer Research Fund Alliance
Ontario Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 16 February 2023
Accepted: 13 June 2024
First Online: 29 July 2024
Competing interests
: X.-K.L., K.S. and P.Y. are inventors on patent applications covering the ACE method. P.Y. is a cofounder, equity holder, board member and consultant of Ultivue, Inc., Spear Bio, Inc. and Digital Biology Inc. The remaining authors declare no competing interests.
